These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29303508)

  • 1. Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells.
    Sohn BH; Park IY; Shin JH; Yim SY; Lee JS
    Exp Mol Med; 2018 Jan; 50(1):e421. PubMed ID: 29303508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells.
    Tardito S; Chiu M; Uggeri J; Zerbini A; Da Ros F; Dall'Asta V; Missale G; Bussolati O
    Curr Cancer Drug Targets; 2011 Oct; 11(8):929-43. PubMed ID: 21834755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
    Lin YT; Chao CC
    Oncotarget; 2015 Nov; 6(36):38999-9017. PubMed ID: 26517516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations.
    Adebayo Michael AO; Ko S; Tao J; Moghe A; Yang H; Xu M; Russell JO; Pradhan-Sundd T; Liu S; Singh S; Poddar M; Monga JS; Liu P; Oertel M; Ranganathan S; Singhi A; Rebouissou S; Zucman-Rossi J; Ribback S; Calvisi D; Qvartskhava N; Görg B; Häussinger D; Chen X; Monga SP
    Cell Metab; 2019 May; 29(5):1135-1150.e6. PubMed ID: 30713111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoexpression of Heat Shock Protein 70, Glypican 3, Glutamine Synthetase, and Beta-Catenin in Hepatocellular Carcinoma After Liver Transplantation: Association Between Positive Glypican 3 and Beta-Catenin With the Presence of Larger Nodules.
    Ataide EC; Perales SR; Silva MG; Filho FC; Sparapani AC; Latuf Filho PF; Stucchi RSB; Vassallo J; Escanhoela CAF; Boin IFSF
    Transplant Proc; 2017 May; 49(4):858-862. PubMed ID: 28457411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of exon 3 β-catenin mutations with glutamine synthetase staining patterns in hepatocellular adenoma and hepatocellular carcinoma.
    Hale G; Liu X; Hu J; Xu Z; Che L; Solomon D; Tsokos C; Shafizadeh N; Chen X; Gill R; Kakar S
    Mod Pathol; 2016 Nov; 29(11):1370-1380. PubMed ID: 27469330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma arising in a pigmented telangiectatic adenoma with nuclear β-catenin and glutamine synthetase positivity: case report and review of the literature.
    Hechtman JF; Raoufi M; Fiel MI; Taouli B; Facciuto M; Schiano TD; Blouin AG; Thung SN
    Am J Surg Pathol; 2011 Jun; 35(6):927-32. PubMed ID: 21572265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagic flux modulation by Wnt/β-catenin pathway inhibition in hepatocellular carcinoma.
    Turcios L; Chacon E; Garcia C; Eman P; Cornea V; Jiang J; Spear B; Liu C; Watt DS; Marti F; Gedaly R
    PLoS One; 2019; 14(2):e0212538. PubMed ID: 30794613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation.
    Lee JM; Yang J; Newell P; Singh S; Parwani A; Friedman SL; Nejak-Bowen KN; Monga SP
    Cancer Lett; 2014 Feb; 343(1):90-7. PubMed ID: 24071572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts.
    Chiu M; Tardito S; Pillozzi S; Arcangeli A; Armento A; Uggeri J; Missale G; Bianchi MG; Barilli A; Dall'Asta V; Campanini N; Silini EM; Fuchs J; Armeanu-Ebinger S; Bussolati O
    Br J Cancer; 2014 Sep; 111(6):1159-67. PubMed ID: 25072259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
    Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I; Pollak Y; Broneshter R; Iancu TC
    FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells.
    Behari J; Zeng G; Otruba W; Thompson MD; Muller P; Micsenyi A; Sekhon SS; Leoni L; Monga SP
    J Hepatol; 2007 May; 46(5):849-57. PubMed ID: 17275129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamine synthetase and hepatocellular carcinoma.
    Jiang J; Hu Y; Fang D; Luo J
    Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102248. PubMed ID: 37979911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
    Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
    Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells.
    Muche S; Kirschnick M; Schwarz M; Braeuning A
    Anticancer Res; 2014 Sep; 34(9):4677-83. PubMed ID: 25202044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations.
    Audard V; Grimber G; Elie C; Radenen B; Audebourg A; Letourneur F; Soubrane O; Vacher-Lavenu MC; Perret C; Cavard C; Terris B
    J Pathol; 2007 Jul; 212(3):345-52. PubMed ID: 17487939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse glutamine synthetase overexpression restricted to areas of peliosis in a β-catenin-activated hepatocellular adenoma: a potential pitfall in glutamine synthetase interpretation.
    Berry RS; Gullapalli RR; Wu J; Morris K; Hanson JA
    Virchows Arch; 2014 Aug; 465(2):241-5. PubMed ID: 24997695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ammonia scavenger and glutamine synthetase inhibitors cocktail in targeting mTOR/β-catenin and MMP-14 for nitrogen homeostasis and liver cancer.
    Elmetwalli A; Nageh A; Youssef AI; Youssef M; Ahmed MAE; Noreldin AE; El-Sewedy T
    Med Oncol; 2023 Dec; 41(1):38. PubMed ID: 38157146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
    Kim MJ; Choi YK; Park SY; Jang SY; Lee JY; Ham HJ; Kim BG; Jeon HJ; Kim JH; Kim JG; Lee IK; Park KG
    Mol Cancer Res; 2017 Sep; 15(9):1230-1242. PubMed ID: 28584024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.